Ascentage Pharma's Olverembatinib Data Presentation at ESMO 2024

Ascentage Pharma's Presentation on Olverembatinib

Ascentage Pharma, a leading global biopharmaceutical company, is set to present updated clinical data on its innovative drug candidate, olverembatinib, at the prestigious ESMO Congress. The presentation will focus on the treatment of patients afflicted with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST). This important event highlights the significant strides being made in oncology research and treatment options available to patients.

ESMO Congress: A Platform for Groundbreaking Research

The ESMO Congress is renowned for showcasing cutting-edge cancer research and advancements in treatment methodologies worldwide. It brings together experts from various fields to discuss the latest findings, making it an essential event for oncologists and researchers globally. Attendance at this year's congress promises to be enlightening, further supporting the progression of cancer therapies.

Olverembatinib: A Revolutionary Treatment Approach

Olverembatinib, a third-generation Tyrosine Kinase Inhibitor (TKI) developed by Ascentage Pharma, is making waves in its clinical applications. Recently, the China CDE has granted the drug clearance to begin a registrational Phase III study. This major milestone signifies Ascentage's commitment to advancing clinical development and expanding treatment horizons for patients worldwide.

Presentation Insights and Schedule

Details of the Mini Oral presentation are as follows:

• **Format:** Mini oral
• **Presentation #:** 1722MO
• **Category:** Sarcoma
• **Date & Time:** Friday, September 13, 2024, 16:30 - 16:35 CEST
• **Speaker:** Dr. Haibo Qiu, MD, PhD, from Sun Yat-sen University Cancer Center

About Ascentage Pharma

Ascentage Pharma has firmly established itself as an integrated biopharmaceutical powerhouse. Focused on discovering and developing therapies that address unmet medical needs, particularly in cancer, the company boasts a diverse pipeline of drug candidates. Their portfolio includes highly potent Bcl-2 inhibitors and next-generation TKIs, which are critical in the fight against various malignancies.

Clinical Trials and Regulatory Successes

To date, Ascentage Pharma has undertaken more than 40 clinical trials across multiple countries and has been successful in navigating the regulatory environment. The company has received various designations, including Priority Review and Breakthrough Therapy Designations for olverembatinib, reflecting its potential impact on treating chronic myeloid leukemia (CML) and beyond.

Strengthening Research and Development

Cultivating collaborations with eminent institutions and biotech companies, Ascentage Pharma's strategic partnerships have bolstered its research capabilities. By wishing to fulfill unmet clinical needs both domestically and globally, the company aims to enhance its R&D initiatives and refine its clinical development processes, yielding significant benefits for patients everywhere.

Frequently Asked Questions

What is the purpose of Ascentage Pharma's presentation at ESMO 2024?

The presentation aims to share updated clinical data on olverembatinib for patients with SDH-deficient GIST, underlining its therapeutic potential.

When and where is the ESMO Congress taking place?

The ESMO Congress is scheduled from September 13 to 17, 2024, with Ascentage Pharma's presentation happening on September 13.

What is olverembatinib and its relevance in cancer treatment?

Olverembatinib is a third-generation TKI designed to treat drug-resistant CML and SDH-deficient GIST, showing promising results in clinical trials.

Who will present the data on olverembatinib?

The presentation will be conducted by Dr. Haibo Qiu of Sun Yat-sen University Cancer Center.

How is Ascentage Pharma contributing to cancer research?

Ascentage Pharma is committed to developing innovative therapies for malignancies, engaging in numerous clinical trials and collaborating with leading institutions.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.